EAM Global Investors’s Krystal Biotech KRYS Stock Holding History

EAM Global Investors’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-28,976	Closed	-$5.27M	–	145
2024 Q3	$5.27M	Buy	28,976 +133	+0.5%	+$25.6K	1.06%	35
2024 Q2	$5.3M	Buy	28,843 +1	+0%	+$168	1.19%	30
2024 Q1	$5.13M	Buy	+28,842	New	+$4.01M	1.19%	30
2023 Q4	–	Sell	-29,517	Closed	-$3.42M	–	131
2023 Q3	$3.42M	Sell	29,517 -5,653	-16%	-$690K	0.93%	68
2023 Q2	$4.13M	Buy	+35,170	New	+$3.59M	1.21%	43
2023 Q1	–	Sell	-21,605	Closed	-$1.71M	–	143
2022 Q4	$1.71M	Hold	21,605	–	–	0.44%	115
2022 Q3	$1.51M	Hold	21,605	–	–	0.4%	133
2022 Q2	$1.42M	Sell	21,605 -354	-2%	-$22K	0.35%	146
2022 Q1	$1.46M	Hold	21,959	–	–	0.27%	184
2021 Q4	$1.54M	Buy	+21,959	New	+$1.28M	0.27%	180
2020 Q2	–	Sell	-30,065	Closed	-$1.3M	–	135
2020 Q1	$1.3M	Sell	30,065 -5	-0%	-$262	0.76%	67
2019 Q4	$1.67M	Sell	30,070 -11,259	-27%	-$552K	0.67%	84
2019 Q3	$1.44M	Buy	41,329 +8,192	+25%	+$366K	0.7%	78
2019 Q2	$1.33M	Buy	+33,137	New	+$1.08M	0.57%	104

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EAM Global Investors's KRYS Position: Q4 2024 in Review

EAM Global Investors sold out of Krystal Biotech (KRYS) in Q4 2024, closing a stake of 28,976 shares — an estimated $5.27M sold.

EAM Global Investors first reported a position in KRYS in Q2 2019 and held it in 14 quarters. The position peaked at $5.3M in Q2 2024. 264 funds tracked by Wall St. Rank hold KRYS as of Q4 2024.

EAM Global Investors reported no remaining Krystal Biotech position as of Q4 2024 after selling out during the quarter.
EAM Global Investors sold 28,976 Krystal Biotech shares in Q4 2024, an estimated $5.27M.
EAM Global Investors first reported a position in Krystal Biotech in Q2 2019 and held it in 14 quarters.
EAM Global Investors's Krystal Biotech position peaked at $5.3M in Q2 2024.
264 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2024.

Based on EAM Global Investors's 13F filing for Q4 2024, filed 13 Feb 2025.